BCA
ALNY icon

Berman Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Berman Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$88K Buy
469
+55
+13% +$10.3K 0.01% 478
2021
Q2 		$70K Buy
414
+266
+180% +$39K 0.01% 467
2021
Q1 		$20K Sell
148
-56
-27% -$8.43K ﹤0.01% 786
2020
Q4 		$26K Buy
204
+15
+8% +$2K 0.01% 598
2020
Q3 		$27K Buy
189
+58
+44% +$8.24K 0.01% 501
2020
Q2 		$19K Buy
131
+42
+47% +$5.66K 0.01% 550
2020
Q1 		$9K Buy
89
+45
+102% +$5.19K ﹤0.01% 680
2019
Q4 		$5K Hold
44
– – ﹤0.01% 958
2019
Q3 		$3K Buy
44
+34
+340% +$2.69K ﹤0.01% 1053
2019
Q2 		$0 Sell
10
-47
-82% -$3.61K ﹤0.01% 1457
2019
Q1 		$5K Buy
57
+52
+1,040% +$4.35K ﹤0.01% 844
2018
Q4 		$0 Buy
+5
New +$385 ﹤0.01% 1120

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Berman Capital Advisors's ALNY Position: Q3 2021 in Review

Berman Capital Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 13% in Q3 2021, buying an estimated $10.3K and bringing the position to 469 shares worth $88K. The position accounts for 0.01% of the portfolio, ranked #478.

Berman Capital Advisors first reported a position in ALNY in Q4 2018 and has held it in 12 quarters since. 404 funds tracked by Wall St. Rank hold ALNY as of Q3 2021.

  • Berman Capital Advisors held 469 shares of Alnylam Pharmaceuticals worth $88K as of Q3 2021.
  • Berman Capital Advisors bought 55 Alnylam Pharmaceuticals shares in Q3 2021, an estimated $10.3K.
  • Alnylam Pharmaceuticals made up 0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #478 holding.
  • Berman Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2018 and has held it in 12 quarters since.
  • 404 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.